Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial (Ophthalmology. 2016;123:1351-1359)

被引：0
|
作者：
Venkatesh, Pradeep [1 ]
机构：
[1] All India Inst Med Sci, Dr Rajendra Prasad Ctr Ophthalm Sci, Dis Retina Vitreous & Uvea, New Delhi, India
来源：
OPHTHALMOLOGY | 2017年 / 124卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：E37 / E38
页数：3
相关论文
共 27 条
  • [1] Re: Wells et al.: Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1359)
    Shanmugam, Mahesh P.
    Harshey, Kaustubh B.
    Ramanjulu, Rajesh
    Mishra, Divyansh K.
    OPHTHALMOLOGY, 2017, 124 (01) : E5 - E5
  • [2] Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358)
    Tornambe, Paul
    OPHTHALMOLOGY, 2017, 124 (03) : E25 - E26
  • [3] Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial (Ophthalmology 2016;123:1351-1358) Reply
    Wells, John A.
    Glassman, Adam R.
    Jampol, Lee M.
    Ayala, Allison
    Bressler, Neil M.
    OPHTHALMOLOGY, 2017, 124 (03) : E26 - E27
  • [4] Re: Wells et al.: Aflibercept, Bevacizumab, or Ranibizumab for diabetic macular edema: two year results from a comparative effectiveness randomized clinical trial REPLY
    Wells, John A.
    Glassman, Adam R.
    Bressler, Neil M.
    Ayala, Allison R.
    Jampol, Lee M.
    OPHTHALMOLOGY, 2017, 124 (04) : E38 - E39
  • [5] Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial
    Wells, John A.
    Glassman, Adam R.
    Ayala, Allison R.
    Jampol, Lee M.
    Bressler, Neil M.
    Bressler, Susan B.
    Brucker, Alexander J.
    Ferris, Frederick L.
    Hampton, G. Robert
    Jhaveri, Chirag
    Melia, Michele
    Beck, Roy W.
    OPHTHALMOLOGY, 2016, 123 (06) : 1351 - 1359
  • [6] Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial
    Ross, Eric L.
    Hutton, David W.
    Stein, Joshua D.
    Bressler, Neil M.
    Jampol, Lee M.
    Glassman, Adam R.
    JAMA OPHTHALMOLOGY, 2016, 134 (08) : 888 - 896
  • [7] Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154)
    Sharma, Ashish
    Kumar, Nilesh
    Kuppermann, Baruch D.
    Francesco, Bandello
    OPHTHALMOLOGY, 2019, 126 (11) : E87 - E88
  • [8] Re: Campochiaro et al.: The Port Delivery System with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 Ladder clinical trial (Ophthalmology. 2019;126:1141-1154) REPLY
    Campochiaro, Peter A.
    Maass, Katie F.
    Singh, Natasha
    Barteselli, Giulio
    OPHTHALMOLOGY, 2019, 126 (11) : E88 - E89
  • [9] Re: Boyer et al.: Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema (Ophthalmology 2014;121:1904-14)
    Ziemssen, Focke
    Agostini, Hansjuergen
    OPHTHALMOLOGY, 2015, 122 (03) : E20 - E21
  • [10] Re: Schaub et al.: Intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy: results from a randomized clinical trial (Ophthalmology. 2022;129:1129-1141)
    van Overdam, Koen A.
    Sebag, Jerry
    OPHTHALMOLOGY, 2023, 130 (06) : E21 - E21
123